GATEWAY trial

The GATEWAY trial is a multi-center, non-randomized, open-label, Phase 1/2 clinical trial designed to assess the safety, tolerability and pharmacological activity of a single intravenous infusion of VTX-801 in adult patients with Wilson disease, prior to and following background WD therapy withdrawal.

The WD Gateway trial has stopped recruitment and is now focused exclusively on long-term follow-up of the already treated patients, with five years of monitoring planned.

Data from this trial will be published as further results become available.

More details on:

https://clinicaltrials.gov/ct2/show/NCT04537377?term=VIVET&draw=2&rank=1